EUVIMEDEUVIMED entdecken
Crossref

CD44: a potential therapeutic target in chronic myeloid leukemia

Rui Shi, Xinle Liu

Die Pharmazie · 01.12.2021 · 76 (12)

DOI: 10.31083/ph.2021.1744 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Die Pharmazie, online erschienen am 01.12.2021. Verfasst von Rui Shi und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Development of tyrosine kinase inhibitors (TKIs) achieved great success in the treatment of chronic phase chronic myeloid leukemia (CML). However, patients with CML still relapse without taking TKIs and cases in the accelerated phase or aggressive blast crisis rarely achieved deep response to TKIs. Drug resistance and persistence of leukemia stem cell (LSC) remain great challenges. BCR-ABL kinase dependent or independent mechanism of action are still far from being understood. To achieve a stable deep molecular response and treatment-free remission, finding new targets, eliminating LSC, reducing recurrence and improving prognosis are problems urgently to be solved. It is revealed that tumor microenvironment is crucial for survival, invasion and metastasis of tumor cells. As an adhesion molecule, CD44, a single-chain transmembrane glycoprotein, is not only being identified as a marker for cancer stem cells, but also plays a crucial role in microenvironmental communication and transmitting intracellular signaling for cell proliferation, differentiation, migration, and contributes to tumorigenesis. In this review, we focus on current data relevant to CD44, and outline CD44 structure, the regulation of CD44, functional properties of CD44 in survival, resistance, CML stem cells as well as the potential CD44-targeting therapy for CML management.

Zitieren

APA

Shi, R., & Liu, X. (2021). CD44: a potential therapeutic target in chronic myeloid leukemia. Die Pharmazie, 76(12). https://doi.org/10.31083/ph.2021.1744

Vancouver

Shi R, Liu X. CD44: a potential therapeutic target in chronic myeloid leukemia. Die Pharmazie. 2021;76(12). doi:10.31083/ph.2021.1744

BibTeX
@article{Shi2021,
  author = {Shi, Rui and Liu, Xinle},
  title = {CD44: a potential therapeutic target in chronic myeloid leukemia},
  journal = {Die Pharmazie},
  year = {2021},
  volume = {76},
  number = {12},
  doi = {10.31083/ph.2021.1744}
}
Kostenlos starten →